ArticleThe Journal of veterinary medical science2026
Baseline serological assessment of foot-and-mouth disease using a non-structural protein antibody lateral flow assay in cattle from an foot-and-mouth disease-free region of Indonesia.
Article in The Journal of veterinary medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease (FMD) is a highly contagious transboundary animal disease causing major economic losses worldwide. This study aimed to establish baseline serological data for FMD in cattle from an FMD-free region of Indonesia using a non-structural protein (NSP) antibody lateral flow assay and to evaluate diagnostic interpretation in a low-prevalence setting. A total of 218 serum samples were collected in East Nusa Tenggara Province. Six samples (2.75%) tested positive, 211 (96.79%) were negative, and one was invalid. The apparent prevalence was 2.75% (95% CI: 1.01-5.90%). Adjusted true prevalence using the Rogan-Gladen estimator was 0%, indicating no detectable infection within the study population rather than definitive absence of infection. Considering assay specificity (96.46%), the observed positives are consistent with expected false-positive results. No clinical signs were observed. These findings suggest no evidence of active FMD circulation within the limits of the study and highlight the importance of cautious interpretation of serological data in low-prevalence settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.